000181803 001__ 181803
000181803 005__ 20240229145657.0
000181803 0247_ $$2doi$$a10.3174/ajnr.A7644
000181803 0247_ $$2ISSN$$a0195-6108
000181803 0247_ $$2ISSN$$a1936-959X
000181803 0247_ $$2altmetric$$aaltmetric:136317742
000181803 0247_ $$2pmid$$apmid:36137662
000181803 037__ $$aDKFZ-2022-02223
000181803 041__ $$aEnglish
000181803 082__ $$a610
000181803 1001_ $$00000-0002-2601-9055$$aTietze, A.$$b0
000181803 245__ $$aImaging Characteristics of CNS Neuroblastoma- FOXR2 : A Retrospective and Multi-Institutional Description of 25 Cases
000181803 260__ $$aOak Brook, Ill.$$bSoc.$$c2022
000181803 3367_ $$2DRIVER$$aarticle
000181803 3367_ $$2DataCite$$aOutput Types/Journal article
000181803 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1668073978_7316
000181803 3367_ $$2BibTeX$$aARTICLE
000181803 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000181803 3367_ $$00$$2EndNote$$aJournal Article
000181803 500__ $$a2022 Sep 22;43(10):1476-1480
000181803 520__ $$aBackground and purpose: The 5th edition of the World Health Organization Classification of CNS tumors defines the CNS neuroblastoma FOXR2 in the group of embryonal tumors. Published clinical outcomes tend to suggest a favorable outcome after resection, craniospinal irradiation, and chemotherapy. This multicenter study aimed to describe imaging features of CNS neuroblastoma-FOXR2, which have been poorly characterized thus far.Materials and methods: On the basis of a previously published cohort of tumors molecularly classified as CNS neuroblastoma-FOXR2, patients with available imaging data were identified. The imaging features on preoperative MR imaging and CT data were recorded by 8 experienced pediatric neuroradiologists in consensus review meetings.Results: Twenty-five patients were evaluated (13 girls; median age, 4.5 years). The tumors were often large (mean, 115 [ SD, 83] mL), showed no (24%) or limited (60%) perilesional edema, demonstrated heterogeneous enhancement, were often calcified and/or hemorrhagic (52%), were always T2WI-hyperintense to GM, and commonly had cystic and/or necrotic components (96%). The mean ADC values were low (687.8 [SD 136.3] × 10-6 mm2/s). The tumors were always supratentorial. Metastases were infrequent (20%) and, when present, were of nodular appearance and leptomeningeal.Conclusions: In our cohort, CNS neuroblastoma FOXR2 tumors showed imaging features suggesting high-grade malignancy and, at the same time, showed characteristics of less aggressive behavior. There are important differential diagnoses, but the results of this study may assist in considering this diagnosis preoperatively.
000181803 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000181803 588__ $$aDataset connected to CrossRef, Journals: inrepo02.dkfz.de
000181803 7001_ $$00000-0001-5979-9337$$aMankad, K.$$b1
000181803 7001_ $$00000-0001-7488-1734$$aLequin, M. H.$$b2
000181803 7001_ $$00000-0002-4582-7226$$aIvarsson, L.$$b3
000181803 7001_ $$00000-0003-2162-515X$$aMirsky, D.$$b4
000181803 7001_ $$00000-0001-5025-3709$$aJaju, A.$$b5
000181803 7001_ $$0P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aKool, Marcel$$b6$$udkfz
000181803 7001_ $$aHoff, K. V.$$b7
000181803 7001_ $$00000-0001-5849-8671$$aBison, B.$$b8
000181803 7001_ $$00000-0001-9844-3464$$aLöbel, U.$$b9
000181803 773__ $$0PERI:(DE-600)2025541-X$$a10.3174/ajnr.A7644$$gp. ajnr;ajnr.A7644v1$$n10$$p1476-1480$$tAmerican journal of neuroradiology$$v23$$x0195-6108$$y2022
000181803 909CO $$ooai:inrepo02.dkfz.de:181803$$pVDB
000181803 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000181803 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000181803 9141_ $$y2022
000181803 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-04
000181803 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-02-04
000181803 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-04
000181803 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bAM J NEURORADIOL : 2021$$d2022-11-16
000181803 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-16
000181803 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-16
000181803 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-16
000181803 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-16
000181803 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-16
000181803 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-16
000181803 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-16
000181803 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2022-11-16
000181803 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000181803 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000181803 980__ $$ajournal
000181803 980__ $$aVDB
000181803 980__ $$aI:(DE-He78)B062-20160331
000181803 980__ $$aI:(DE-He78)HD01-20160331
000181803 980__ $$aUNRESTRICTED